BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 18753192)

  • 1. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.
    Szeto CC; Kwan BC; Lai FM; Tam LS; Li EK; Chow KM; Gang W; Li PK
    Rheumatology (Oxford); 2008 Nov; 47(11):1678-81. PubMed ID: 18753192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective treatment of young patients with pediatric-onset, long-standing lupus nephritis with tacrolimus given as a single daily dose: an open-label pilot study.
    Tanaka H; Oki E; Tsugawa K; Nonaka K; Suzuki K; Ito E
    Lupus; 2007; 16(11):896-900. PubMed ID: 17971363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine.
    Mok CC; Ying KY; Yim CW; Ng WL; Wong WS
    Lupus; 2009 Oct; 18(12):1091-5. PubMed ID: 19762384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
    Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J
    Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.
    Tanaka H; Oki E; Tsuruga K; Yashiro T; Hanada I; Ito E
    Clin Nephrol; 2009 Dec; 72(6):430-6. PubMed ID: 19954719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive treatment of the glomerulonephritis of systemic lupus.
    Faedda R; Palomba D; Satta A; Pirisi M; Tanda F; Bartoli E
    Clin Nephrol; 1995 Dec; 44(6):367-75. PubMed ID: 8719548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic lupus erythematosus in Thai children: clinicopathologic findings and outcome in 82 patients.
    Pattaragarn A; Sumboonnanonda A; Parichatikanond P; Supavekin S; Suntornpoch V; Vongjirad A
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S232-41. PubMed ID: 16856445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.
    Illei GG; Yarboro CH; Kuroiwa T; Schlimgen R; Austin HA; Tisdale JF; Chitkara P; Fleisher T; Klippel JH; Balow JE; Boumpas DT
    Rheumatology (Oxford); 2007 Jun; 46(6):952-6. PubMed ID: 17317716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
    Sakai R; Kurasawa T; Nishi E; Kondo T; Okada Y; Shibata A; Nishimura K; Chino K; Okuyama A; Takei H; Nagasawa H; Amano K
    Lupus; 2018 Feb; 27(2):273-282. PubMed ID: 28683654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
    Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
    Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
    Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
    Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis.
    Demircin G; Oner A; Erdoğan O; Delibaş A; Baysun S; Bülbül M; Bek K; Oksal A
    Ren Fail; 2008; 30(6):603-9. PubMed ID: 18661410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis.
    Li X; Ren H; Zhang Q; Zhang W; Wu X; Xu Y; Shen P; Chen N
    Nephrol Dial Transplant; 2012 Apr; 27(4):1467-72. PubMed ID: 21917733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors of diffuse proliferative lupus nephritis.
    Lim CS; Chin HJ; Jung YC; Kim YS; Ahn C; Han JS; Kim S; Lee JS
    Clin Nephrol; 1999 Sep; 52(3):139-47. PubMed ID: 10499308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
    Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
    Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine A in treatment of membranous lupus nephropathy.
    Hu W; Liu Z; Shen S; Li S; Yao X; Chen H; Li L
    Chin Med J (Engl); 2003 Dec; 116(12):1827-30. PubMed ID: 14687467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis.
    Lee T; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ
    Lupus; 2010 Jul; 19(8):974-80. PubMed ID: 20581020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.